- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Tranexamic Acid fails to increase incidence of same-day discharge among Holmium Laser Prostate Surgery patients
U.S.A.: The inclusion of Tranexamic Acid (TXA) did not increase the incidence of same-day discharge or decrease the risk of complications in patients receiving HoLEP, according to prospective randomized research published in the Journal of Endourology.
To stop bleeding during orthopedic surgeries, tranexamic acid (TXA), a clot-promoting drug, is used. TXA has advantages in percutaneous surgery, according to urologists. Surgery for benign prostatic hyperplasia might cause hematuria, which could delay discharge or need ER visits.
The outcomes of same-day holmium laser enucleation of the prostate (HoLEP) were examined, and the influence of the addition of a single dosage of tranexamic acid (TXA) was assessed in this study.
110 patients receiving HoLEP were prospectively randomized from September 2021 to January 2022 to receive either 1 gram of TXA following induction or no treatment at all. Rate of successful same-day (SDD) discharge was the primary result. The transfusion rate, same-day catheter removal, length of stay (LOS), and 90-day complications were considered secondary outcomes. 110 individuals should be enrolled, according to power analysis, to detect a 25% difference in the SDD rate.
Key highlights of the study:
- Between the control (n=55) and TXA (n=55) groups, there were no differences in the patient demographics or prostate characteristics (all p>0.05).
- Between the control and TXA groups, the overall success rate of SDD was the same (49/55 (89%) vs. 51/55 (93%), p=0.74).
- Only 3/110 (2.7%) of the participants had a LOS >24 hours, and the median LOS (hh:mm) did not differ across groups (03:07 vs. 02:50, p=0.23).
- 99/110 (90%) patients had successful same-day catheter removal, with no difference between groups (49/55 vs. 50/55, p=0.99).
- Operative parameters (time, energy, specimen weight), as well as postoperative complications (all p>0.05), did not differ between groups.
- No patients needed blood transfusions, and there were no significant postoperative sequelae within 90 days (Clavien-dindo IIIb).
Although safe, TXA treatment had little impact on same-day release after HoLEP, concluded the authors.
REFERENCE
Assmus MA, Lee MS, Helon JW, Krambeck A. Tranexamic Acid Does Not Improve Outcomes of Holmium Laser Enucleation of the Prostate (HoLEP): A Prospective Randomized, Controlled Trial. J Endourol. 2022 Oct 12. doi: 10.1089/end.2022.0407. Epub ahead of print. PMID: 36222618.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751